Sugi Predict

Sugi Predict / Compounds / SCHEMBL6042341

SCHEMBL6042341

SCHEMBL6042341

COCCCOc1cc(CCl)cc2c(OC)cccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 6/20 0.42
▸ HPGD P15428 9/20 0.40
▸ L3MBTL1 Q9Y468 8/20 0.40
▸ MAPT P10636 6/20 0.40
▸ LMNA P02545 3/20 0.40
▸ MAPK1 P28482 2/20 0.40
▸ NPC1 O15118 4/20 0.39
▸ RAB9A P51151 4/20 0.39
▸ TDP1 Q9NUW8 2/20 0.39
▸ CYP1A2 P05177 3/20 0.38
▸ CYP2C9 P11712 3/20 0.38
▸ CYP2C19 P33261 3/20 0.38
▸ CYP3A4 P08684 2/20 0.38
▸ TTR P02766 1/20 0.38
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ RECQL P46063 1/20 0.37
▸ HTR1A P08908 2/20 0.36
▸ ADRA1D P25100 2/20 0.36
▸ ADRA1A P35348 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6042539 0.89 SMN1; SMN2 (0.42) SMN1; SMN2HPGDL3MBTL1MAPTLMNA
SCHEMBL6041292 0.85 TTR (0.45) SMN1; SMN2HPGDLMNATTRMEN1
SCHEMBL670195 0.84 SYK (0.44) MAPTTTRKMT2AADRA1DADRA1A
SCHEMBL6041873 0.82 NR2E1 (0.38) SMN1; SMN2LMNAMAPK1CYP1A2CYP2C9
SCHEMBL15173216 0.76 TTR (0.50) TTRATM
SCHEMBL6950752 0.76 MRGPRX4 (0.50) HPGDLMNANPC1RAB9ACYP2C9
SCHEMBL18561728 0.73 SMN1; SMN2 (0.48) SMN1; SMN2L3MBTL1MAPK1TDP1GPR84
SCHEMBL671178 0.72 CALM1 (0.46) MAPTKMT2AMRGPRX4
SCHEMBL6042172 0.72 MRGPRX4 (0.41) HPGDMAPTLMNAMAPK1CYP3A4
SCHEMBL6041661 0.72 NR2E1 (0.39) SMN1; SMN2LMNAMAPK1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060079533-A1 Methods of treating alzheimer's disease NIEMAN JAMES A 2006-04-13 — — US disclosed
EP-0863875-B1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY HOFFMANN LA ROCHE (CH) 2003-06-04 — — EP disclosed
WO-2002076440-A2 METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES ELAN PHARMACEUTICALS, INC. (US) 2002-10-03 — — WO disclosed
US-6150526-A Piperidine derivative having renin inhibiting activity HOFFMANN-LA ROCHE INC. (US) 2000-11-21 — — US disclosed
US-6051712-A PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS HOFFMANN-LA ROCHE INC. (US) 2000-04-18 — — US disclosed
EP-0863875-A1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY F. HOFFMANN-LA ROCHE AG (CH) 1998-09-16 — — EP disclosed
WO-1997009311-A1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY F. HOFFMANN-LA ROCHE AG (CH) 1997-03-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079533-A1 Methods of treating alzheimer's disease BACE1, PSEN1, PSEN2 SMN1; SMN2 1096/4885HPGD 1509/4885L3MBTL1 1516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.